Clinical Trial

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-25.
Status change: Not Yet Recruiting → Recruiting 2024-12-09
Trial Details
NCT Number NCT06708572
Lead Sponsor National Liver Institute, Egypt
Conditions Granulocyte Colony-stimulating Factor, Biliary Atresia
Enrollment 40 participants
Start Date 2024-12
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-11